Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Accumulated Expenses (2022 - 2025)

Taysha Gene Therapies' Other Accumulated Expenses history spans 4 years, with the latest figure at $800000.0 for Q2 2025.

  • For Q2 2025, Other Accumulated Expenses rose 2.96% year-over-year to $800000.0; the TTM value through Jun 2025 reached $800000.0, up 2.96%, while the annual FY2024 figure was $752000.0, 4.01% up from the prior year.
  • Other Accumulated Expenses for Q2 2025 was $800000.0 at Taysha Gene Therapies, up from $752000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.6 million in Q1 2022 and bottomed at $650000.0 in Q4 2022.
  • The 4-year median for Other Accumulated Expenses is $752000.0 (2024), against an average of $827000.0.
  • The largest annual shift saw Other Accumulated Expenses tumbled 56.49% in 2023 before it increased 13.6% in 2024.
  • A 4-year view of Other Accumulated Expenses shows it stood at $650000.0 in 2022, then grew by 11.23% to $723000.0 in 2023, then increased by 4.01% to $752000.0 in 2024, then rose by 6.38% to $800000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Other Accumulated Expenses are $800000.0 (Q2 2025), $752000.0 (Q4 2024), and $777000.0 (Q2 2024).